v3.25.1
Critical accounting judgments and key sources of estimation uncertainty - IFRS 15 - Revenue recognition Gilead (Details)
 12 Months Ended
May 30, 2024
USD ($)
Dec. 31, 2024
EUR (€)
Dec. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Critical accounting estimates and judgments            
Contribution to Alfasigma   € (40,000,000)        
Deferred income   1,071,352,000     € 1,327,463,000 € 1,989,230,000
Goodwill   70,010,000     69,557,000 69,813,000
Intangible assets other than goodwill   € 164,862,000     127,906,000  
Duration Of Forecast Of Future Cash Flows   16 years 16 years      
Minimum Duration Of Forecast Of Future Cash Flows For Which It Becomes Less verifiable And More Assumptions.   5 years 5 years      
Filgotinib Performance Obligation Member            
Critical accounting estimates and judgments            
Deferred income         26,300,000  
Exclusive rights            
Critical accounting estimates and judgments            
Intangible assets other than goodwill   € 114,456,000     71,929,000  
Cell Point Acquisition            
Critical accounting estimates and judgments            
Goodwill   62,400,000       62,444,000
Contingent consideration [member] | Cell Point Acquisition            
Critical accounting estimates and judgments            
Contingent Consideration   € 20,600,000     21,000,000  
Adaptimmune Collaboration [member]            
Critical accounting estimates and judgments            
Upfront Exclusivity Payment | $ $ 70,000,000          
Research and development funding payment. | $ $ 15,000,000          
Upfront Exclusive Research And Development Payable | $       $ 15,000,000    
Deferred Expenses | $       15,000,000    
Adaptimmune Collaboration [member] | Exclusive rights            
Critical accounting estimates and judgments            
Intangible assets other than goodwill | $       $ 70,000,000    
Gilead | Collaboration agreement for filgotinib            
Critical accounting estimates and judgments            
Deferred income         € 26,268,000 € 456,352,000
First Payment [member] | Adaptimmune Collaboration [member]            
Critical accounting estimates and judgments            
Upfront Exclusivity Payment | $     $ 70,000,000      
Second Payment [member] | Adaptimmune Collaboration [member]            
Critical accounting estimates and judgments            
Research and development funding payment. | $     $ 15,000,000